Granulocyte Colony-Stimulating Factor for Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study of Iranian Patients.
10.3988/jcn.2015.11.2.164
- Author:
Nasibeh AMIRZAGAR
1
;
Shahriar NAFISSI
;
Abbas TAFAKHORI
;
Amirhossein MODABBERNIA
;
Aliakbar AMIRZARGAR
;
Majid GHAFFARPOUR
;
Bahaddin SIROOS
;
Mohammad Hossein HARIRCHIAN
Author Information
1. Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. harirchn@hotmail.com
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
amyotrophic lateral sclerosis;
ALS Functional Rating Scale;
granulocyte colony-stimulating factor;
CD34+/CD133+ cells;
monocyte chemoattractant protein-1;
compound motor action potential
- MeSH:
Amyotrophic Lateral Sclerosis*;
Cell Count;
Chemokine CCL2;
Disease Progression;
Female;
Granulocyte Colony-Stimulating Factor*;
Humans;
Neural Conduction
- From:Journal of Clinical Neurology
2015;11(2):164-171
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND PURPOSE: The aim of this study was to determine the efficacy and tolerability of granulocyte colony-stimulating factor (G-CSF) in subjects with amyotrophic lateral sclerosis (ALS). METHODS: Forty subjects with ALS were randomly assigned to two groups, which received either subcutaneous G-CSF (5 microg/kg/q12h) or placebo for 5 days. The subjects were then followed up for 3 months using the ALS Functional Rating Scale-Revised (ALSFRS-R), manual muscle testing, ALS Assessment Questionnaire-40, and nerve conduction studies. CD34+/CD133+ cell count and monocyte chemoattractant protein-1 (MCP-1) levels were evaluated at baseline. RESULTS: The rate of disease progression did not differ significantly between the two groups. The reduction in ALSFRS-R scores was greater in female subjects in the G-CSF group than in their counterparts in the placebo group. There was a trend toward a positive correlation between baseline CSF MCP-1 levels and the change in ALSFRS-R scores in both groups (Spearman's rho=0.370, p=0.070). CONCLUSIONS: With the protocol implemented in this study, G-CSF is not a promising option for the treatment of ALS. Furthermore, it may accelerate disease progression in females.
